Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Feb 05, 2024

Torrent Pharma Q3 Results Review - India, Latin America Drive Earnings: Motilal Oswal

Torrent Pharma Q3 Results Review - India, Latin America Drive Earnings: Motilal Oswal
Assortment of colorful pills arranged for photograph. (Source: freepik)

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Torrent Pharmaceuticals Ltd. delivered an in-line operating performance in Q3 FY24. Healthy Ebitda growth of 18% YoY was driven by superior growth in domestic formulation and LatAm.

The lack of approvals and marginal price erosion in base business in the U.S. affected the overall performance to some extent.

We marginally lower our FY24 estimate by 3% to factor in lower other income. We maintain our estimates for FY25/FY26. We value Torrent Phram at 30 times 12 months forward earnings to arrive at a target price of Rs 2,540.

Torrent Pharma continues to build levers for its branded generics segment in DF/LATAM through a focused approach on existing brands, selective/differentiated product launches, and the addition of MRs to expand reach.

Further, it is also gearing up for launches in the U.S. generics segment from its Dahej site. Tender wins are improving its growth prospects in Germany as well.

Accordingly, we expect a 30% earnings compound annual growth rate over FY24-25. Having said this, the valuation largely factors in this upside in earnings. Retain 'Neutral' on the stock.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search